References
- Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Common 2005;333:328–335
- Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383–390
- Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275–278
- Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short term study. Retina 2006;26:279–284
- Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:1727–1730
- Manzano RPA, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab. Retina 2006;26:257–261
- Macky TA, Mahgoub MM. Electrophysiological assessment of optic nerve and retinal functions following intravitreal injection of bevacizumab (avastin). J Ocul Pharmacol Ther 2012;28:159–165
- Sari A, Adiguzel U, Canacankatan N, et al. Effects of intravitreal bevacizumab in repeated doses: an experimental study. Retina 2009;29:1346–1355
- Van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2012;31:1149–1169
- Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855–859
- Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50:4807–4813
- Matsuyama K, Ogata N, Matsuoka M, et al. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010;94:1215–1218
- Matsuyama K, Ogata N, Matsuoka M, et al. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes. J Ocul Pharmacol Ther 2011;27:379–383
- Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration. Ophthalmology 2012;119:1399–1411
- Lowry OH, Rosebrough NJ, Farr Al, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265–275
- Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005;69:25–33
- Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age related macular degeneration: two-year results. Ophthalmology 2012;119:1388–1398
- Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012;153:327–333
- Hård AL, Hellström A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment-a review. Acta Paediatr 2011;100:1523–1527
- Chuang LH, Wu WC, Yeung L, et al. Serum concentration of bevacizumab after intravitreal injection in experimental branch retinal vein occlusion. Ophthalmic Res 2011;45:31–35
- Artunay O, Yuzbasioglu E, Rasier R, et al. Posterior reversible encephalopathy after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy. J Ocul Pharmacol Ther 2010;26:301–303
- Johnson D, Hollands H, Brox A, Sharma S. Tonic-clonic seizures following intravitreal bevacizumab injection. Can J Ophthalmol 2010;45:186–187
- Rasier R, Artunay O, Yuzbasioglu E, et al. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye 2009;23:1714–1718
- Campbell RJ, Gill SS, Bronskill SE, et al. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ 2012;345:e4203
- Deile JM, Worthmann K, Saleem M, et al. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol 2009;297:1656–1667
- Anto HR, Hyman GF, Li JP, et al. Membranous nephropathy following intravitreal injection of bevacizumab. Can J Ophthalmol 2012;47:84–86